Accelerate Historical Cash Flow

AXDX Stock

USD 0.70 0.16 18.60%

Analysis of Accelerate Diagnostics cash flow over time is an excellent tool to project Accelerate Diagnostics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 2.7 M or Begin Period Cash Flow of 22.8 M as it is a great indicator of Accelerate Diagnostics ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Accelerate Diagnostics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Accelerate Diagnostics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

About Accelerate Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Accelerate balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Accelerate's non-liquid assets can be easily converted into cash.

Accelerate Diagnostics Cash Flow Chart

At this time, Accelerate Diagnostics' Total Cashflows From Investing Activities is fairly stable compared to the past year. Cash Flows Other Operating is likely to rise to about 571.7 K in 2025, whereas Free Cash Flow is likely to drop (25.4 M) in 2025.

Begin Period Cash Flow End Period Cash Flow Change To Netincome Issuance Of Capital Stock

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most accounts from Accelerate Diagnostics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Total Cashflows From Investing Activities is fairly stable compared to the past year. Cash Flows Other Operating is likely to rise to about 571.7 K in 2025, whereas Free Cash Flow is likely to drop (25.4 M) in 2025.

Accelerate Diagnostics cash flow statement Correlations

	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	End Period Cash Flow	Stock Based Compensation	Sale Purchase Of Stock	Change To Account Receivables	Change To Liabilities	Change To Inventory	Dividends Paid	Change Receivables	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Investments	Net Borrowings	Change To Operating Activities	Exchange Rate Changes	Issuance Of Capital Stock
Change In Cash		0.2	-0.15	-0.6	-0.24	-0.04	0.09	0.2	0.56	-0.02	0.36	-0.06	0.17	-0.39	-0.01	-0.03	0.98	-0.42	-0.03	0.21	0.24	-0.18	0.02	-0.01
Free Cash Flow	0.2		0.51	-0.67	-0.7	-0.2	-0.39	0.96	-0.46	-0.81	0.13	0.53	-0.08	0.47	0.56	0.47	0.25	0.25	-0.83	-0.22	-0.49	-0.12	-0.33	-0.12
Change In Working Capital	-0.15	0.51		-0.11	-0.01	0.04	-0.25	0.39	-0.3	-0.52	0.09	0.49	0.41	0.86	0.05	0.24	-0.05	0.61	-0.52	-0.12	-0.67	0.14	-0.61	0.3
Begin Period Cash Flow	-0.6	-0.67	-0.11		0.43	0.0	0.46	-0.62	0.33	0.46	0.14	-0.17	-0.2	0.19	-0.42	-0.07	-0.66	-0.03	0.45	0.01	-0.11	0.15	-0.1	-0.07
Depreciation	-0.24	-0.7	-0.01	0.43		0.64	0.12	-0.82	0.15	0.5	-0.14	-0.23	0.51	-0.12	-0.53	-0.49	-0.25	0.05	0.69	0.35	0.12	-0.1	0.2	0.48
Other Non Cash Items	-0.04	-0.2	0.04	0.0	0.64		-0.3	-0.43	-0.06	0.24	-0.24	0.09	0.21	-0.03	-0.3	-0.16	-0.08	-0.03	0.51	0.43	-0.09	-0.28	-0.05	0.41
Capital Expenditures	0.09	-0.39	-0.25	0.46	0.12	-0.3		-0.26	0.59	0.31	0.59	-0.3	0.04	-0.2	-0.44	-0.16	0.03	-0.27	0.33	-0.33	0.31	0.19	0.39	-0.3
Net Income	0.2	0.96	0.39	-0.62	-0.82	-0.43	-0.26		-0.4	-0.83	0.2	0.43	-0.13	0.37	0.6	0.44	0.25	0.21	-0.89	-0.33	-0.37	-0.04	-0.24	-0.28
End Period Cash Flow	0.56	-0.46	-0.3	0.33	0.15	-0.06	0.59	-0.4		0.46	0.57	-0.24	-0.02	-0.25	-0.45	-0.1	0.47	-0.53	0.43	0.25	0.17	-0.05	-0.08	-0.09
Stock Based Compensation	-0.02	-0.81	-0.52	0.46	0.5	0.24	0.31	-0.83	0.46		-0.12	-0.44	-0.16	-0.43	-0.5	-0.29	-0.1	-0.32	0.9	0.26	0.37	0.02	0.29	0.33
Sale Purchase Of Stock	0.36	0.13	0.09	0.14	-0.14	-0.24	0.59	0.2	0.57	-0.12		-0.02	-0.06	0.17	-0.11	0.03	0.34	-0.19	-0.16	0.09	-0.33	-0.26	-0.02	-0.11
Change To Account Receivables	-0.06	0.53	0.49	-0.17	-0.23	0.09	-0.3	0.43	-0.24	-0.44	-0.02		-0.22	0.58	0.28	0.89	-0.04	-0.18	-0.36	-0.18	-0.45	-0.13	-0.62	-0.13
Change To Liabilities	0.17	-0.08	0.41	-0.2	0.51	0.21	0.04	-0.13	-0.02	-0.16	-0.06	-0.22		0.0	-0.26	-0.58	0.23	0.5	0.0	-0.04	0.15	0.23	0.15	0.43
Change To Inventory	-0.39	0.47	0.86	0.19	-0.12	-0.03	-0.2	0.37	-0.25	-0.43	0.17	0.58	0.0		0.15	0.45	-0.34	0.49	-0.48	-0.15	-0.84	0.11	-0.75	0.18
Dividends Paid	-0.01	0.56	0.05	-0.42	-0.53	-0.3	-0.44	0.6	-0.45	-0.5	-0.11	0.28	-0.26	0.15		0.32	0.09	0.06	-0.55	-0.13	-0.15	-0.02	-0.18	-0.18
Change Receivables	-0.03	0.47	0.24	-0.07	-0.49	-0.16	-0.16	0.44	-0.1	-0.29	0.03	0.89	-0.58	0.45	0.32		-0.03	-0.38	-0.33	-0.25	-0.32	-0.07	-0.59	-0.38
Cash And Cash Equivalents Changes	0.98	0.25	-0.05	-0.66	-0.25	-0.08	0.03	0.25	0.47	-0.1	0.34	-0.04	0.23	-0.34	0.09	-0.03		-0.36	-0.12	0.24	0.2	-0.2	-0.01	-0.02
Cash Flows Other Operating	-0.42	0.25	0.61	-0.03	0.05	-0.03	-0.27	0.21	-0.53	-0.32	-0.19	-0.18	0.5	0.49	0.06	-0.38	-0.36		-0.39	-0.26	-0.32	0.44	-0.09	0.47
Change To Netincome	-0.03	-0.83	-0.52	0.45	0.69	0.51	0.33	-0.89	0.43	0.9	-0.16	-0.36	0.0	-0.48	-0.55	-0.33	-0.12	-0.39		0.28	0.42	-0.07	0.35	0.23
Investments	0.21	-0.22	-0.12	0.01	0.35	0.43	-0.33	-0.33	0.25	0.26	0.09	-0.18	-0.04	-0.15	-0.13	-0.25	0.24	-0.26	0.28		-0.31	-0.77	-0.11	0.25
Net Borrowings	0.24	-0.49	-0.67	-0.11	0.12	-0.09	0.31	-0.37	0.17	0.37	-0.33	-0.45	0.15	-0.84	-0.15	-0.32	0.2	-0.32	0.42	-0.31		0.38	0.64	-0.23
Change To Operating Activities	-0.18	-0.12	0.14	0.15	-0.1	-0.28	0.19	-0.04	-0.05	0.02	-0.26	-0.13	0.23	0.11	-0.02	-0.07	-0.2	0.44	-0.07	-0.77	0.38		-0.07	0.02
Exchange Rate Changes	0.02	-0.33	-0.61	-0.1	0.2	-0.05	0.39	-0.24	-0.08	0.29	-0.02	-0.62	0.15	-0.75	-0.18	-0.59	-0.01	-0.09	0.35	-0.11	0.64	-0.07		-0.03
Issuance Of Capital Stock	-0.01	-0.12	0.3	-0.07	0.48	0.41	-0.3	-0.28	-0.09	0.33	-0.11	-0.13	0.43	0.18	-0.18	-0.38	-0.02	0.47	0.23	0.25	-0.23	0.02	-0.03

Click cells to compare fundamentals

Accelerate Diagnostics Account Relationship Matchups

Accelerate Diagnostics cash flow statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Change In Cash	(25.2M)	4.1M	(5.0M)	(22.8M)	3.0M	3.1M
Free Cash Flow	(51.8M)	(47.9M)	(49.3M)	(41.2M)	(24.2M)	(25.4M)
Change In Working Capital	(3.3M)	(102K)	2.3M	4.9M	2.6M	2.7M
Begin Period Cash Flow	61.0M	35.8M	39.9M	34.9M	12.1M	22.8M
Other Cashflows From Financing Activities	6.1M	380K	39K	(3.7M)	28.5M	29.9M
Depreciation	3.0M	2.5M	3M	3.3M	3.4M	3.6M
Other Non Cash Items	11.2M	11.5M	(2.1M)	7.8M	15.5M	16.2M
Capital Expenditures	1.4M	603K	554K	1.0M	509K	712.0K
Total Cash From Operating Activities	(50.4M)	(47.3M)	(48.7M)	(40.2M)	(24.2M)	(25.4M)
Net Income	(78.2M)	(77.7M)	(62.5M)	(61.6M)	(50.0M)	(47.5M)
End Period Cash Flow	35.8M	39.9M	34.9M	12.1M	15.1M	23.5M
Total Cash From Financing Activities	11.6M	43.2M	31.6M	9.0M	27.1M	26.8M
Stock Based Compensation	16.5M	22.0M	10.6M	5.4M	4.4M	4.2M
Sale Purchase Of Stock	1.5M	359K	326K	224K	201.6K	191.5K
Change To Account Receivables	1.6M	(770K)	(96K)	(234K)	440K	462K
Change To Liabilities	(339K)	(1.9M)	348K	3.0M	3.5M	3.6M
Change To Inventory	(1.4M)	(415K)	(236K)	446K	(50K)	(52.5K)
Total Cashflows From Investing Activities	52.8M	13.6M	8.3M	12.4M	14.3M	15.0M
Change Receivables	86K	(1.4M)	1.6M	(770K)	(693K)	(658.4K)
Cash And Cash Equivalents Changes	37.7M	(5.2M)	(25.2M)	4.1M	3.7M	3.3M
Cash Flows Other Operating	(1.2M)	(698K)	(2.3M)	605K	544.5K	571.7K
Other Cashflows From Investing Activities	(1.4M)	(603K)	(554K)	(1.0)	(509K)	(534.5K)
Change To Netincome	13.4M	17.6M	16.4M	7.2M	8.3M	11.6M
Investments	15.0M	8.9M	12.4M	14.6M	(509K)	(534.5K)
Change To Operating Activities	(2.1M)	(2.7M)	735K	(431K)	(387.9K)	(368.5K)
Exchange Rate Changes	(130K)	(86K)	(78K)	(90K)	(81K)	(77.0K)
Issuance Of Capital Stock	359K	43.2M	33.1M	4M	30.0M	17.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Accelerate Historical Cash Flow

About Accelerate Cash Flow Analysis

Accelerate Diagnostics Cash Flow Chart

Begin Period Cash Flow

Accelerate Diagnostics cash flow statement Correlations

Accelerate Diagnostics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Accelerate Diagnostics cash flow statement Accounts

Also Currently Popular

Additional Tools for Accelerate Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Cash Equivalents Changes	+ 0.98	Change In Cash
Net Income	+ 0.96	Free Cash Flow
Change To Netincome	+ 0.9	Stock Based Compensation
Change Receivables	+ 0.89	Change To Account Receivables
Change To Inventory	+ 0.86	Change In Working Capital
Change To Netincome	+ 0.69	Depreciation

Change To Netincome	- 0.89	Net Income
Net Borrowings	- 0.84	Change To Inventory
Stock Based Compensation	- 0.83	Net Income
Change To Netincome	- 0.83	Free Cash Flow
Net Income	- 0.82	Depreciation
Stock Based Compensation	- 0.81	Free Cash Flow